Pulmonary arterial hypertension is a progressive disorder characterized by elevated pressure in the pulmonary arteries, leading to right heart strain, reduced exercise capacity, and eventually right heart failure if untreated. The condition can occur as an isolated disease or be associated with connective tissue disorders, congenital heart disease, chronic lung diseases, or exposure to certain drugs and toxins. Diagnosis of pulmonary arterial hypertension relies on a combination of echocardiography, right heart catheterization, imaging studies, and laboratory evaluation to confirm elevated pressures and rule out secondary causes. Management strategies are multifaceted, focusing on reducing pulmonary vascular resistance, improving functional status, and preventing disease progression. Pharmacologic therapies include vasodilators such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin analogs, and soluble guanylate cyclase stimulators, often used in combination for better outcomes. Non-pharmacological approaches, such as supervised exercise training, oxygen therapy, anticoagulation when indicated, and patient education, complement medical therapy. Pulmonary arterial hypertension care also emphasizes regular monitoring to assess treatment response and adjust therapy as needed. Multidisciplinary collaboration between pulmonologists, cardiologists, and specialized care teams is vital to ensure comprehensive management. Advances in research are exploring novel pathways and targeted therapies aimed at improving survival and quality of life. By combining timely diagnosis, evidence-based treatment, and supportive care, pulmonary arterial hypertension management helps reduce complications, enhance functional ability, and improve long-term outcomes for affected individuals.
Title : Novel signaling mechanisms and innovative therapeutic strategies of pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Changing population immunity to COVID-19 in the context of infection, vaccination and emerging SARS-CoV-2 variants
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Susceptibility to SARS-CoV-2 infection and nasal air conditioning ability
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Comparative evaluation of DECAF and BAP 65 scores in predicting outcomes of COPD exacerbations among in patients at Vicente Sotto Memorial Medical Center
Allanys Joy Q Pino, Vicente Sotto Memorial Medical Center, Philippines
Title :
Saurabh Chattopadhyay, University of Kentucky College of Medicine, United States
Title : Personalized and precision Medicine (PPM) as a unique healthcare model through biodesign driven and inspired biotech, translational applications and pulmonology related marketing to secure the human healthcare, wellness and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation